Endocrine Abstracts

First generation somatostatin receptor ligands (SRL) are the first-line drugs in primary acromegaly treatment or after surgical failure in patients with active acromegaly. In previous studies we confirmed the association of the expression of SSTR2, Ki67 and E-cadherin (CDH1) in responsive GH-secreting adenomas response to SRL. Moreover, E-cadherin showed a greater predictive capacity than most of the markers described. Loss of E-cadherin is a typical mark of ...